Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H11N2O3.K |
| Molecular Weight | 222.2828 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].CCC1(CC)C(=O)NC(=O)[N-]C1=O
InChI
InChIKey=FOQIEWZXCHZONC-UHFFFAOYSA-M
InChI=1S/C8H12N2O3.K/c1-3-8(4-2)5(11)9-7(13)10-6(8)12;/h3-4H2,1-2H3,(H2,9,10,11,12,13);/q;+1/p-1
Barbital, the one of the series of barbiturates, has hypnotic, sedative, and anticonvulsant properties and used under the trade name Veronal. It calmed manic patients and helped melancholic patients to sleep and was an effective inducer of sleep in insomniacs, but at the same time compound could induced dependence. It was substituted by the butyl analog, butobarbital, which was three times stronger and its period of action was much shorter due to its lipophilicity. Barbital is a ligand of GABA-receptor complex and in addition, it could have another target, a creatine kinase.
CNS Activity
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
300 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3860 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Condition: drug withdrawal Age Group: 19 years Sex: M Population Size: 1 Sources: |
Other AEs: Coma... |
250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
Other AEs: Dizziness, Drug intoxication... Other AEs: Dizziness Sources: Drug intoxication Euphoric Tiredness |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Coma | 5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Condition: drug withdrawal Age Group: 19 years Sex: M Population Size: 1 Sources: |
|
| Dizziness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Drug intoxication | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Euphoric | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Tiredness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Modifying potential of thirty-one chemicals on the short-term development of gamma-glutamyl transpeptidase-positive foci in diethylnitrosamine-initiated rat liver. | 1984 Oct |
|
| Induction of CYP2B1 mediated pentoxyresorufin O-dealkylase activity in different species, sex and tissue by prototype 2B1-inducers. | 1995 Mar 30 |
|
| Supramolecular synthons based on N-H...N and C-H...O hydrogen bonds. Crystal engineering of a helical structure with 5,5-diethylbarbituric acid. | 2002 Sep 7 |
|
| Biochemical mechanism of the effect of barbital on rifamycin B biosynthesis by Amycolatopsis mediterranei (M18 strain). | 2003 |
|
| Isolation and characterization of anticomplementary beta-glucans from the shoots of bamboo Phyllostachys edulis. | 2003 Jan |
|
| Complexation of phenolic guests by endo- and exo-hydrogen-bonded receptors. | 2003 Jul 21 |
|
| Rational design of the first closed coordination capsule with octahedral outer shape. | 2004 May 3 |
|
| The history of barbiturates a century after their clinical introduction. | 2005 Dec |
|
| Selective self-organization of guest molecules in self-assembled molecular boxes. | 2005 Sep 14 |
|
| Proximal visceral endoderm and extraembryonic ectoderm regulate the formation of primordial germ cell precursors. | 2007 Dec 20 |
|
| Metabolization of porphyrinogenic agents in brain: involvement of the phase I drug metabolizing system. A comparative study in liver and kidney. | 2007 Sep |
|
| Surviving mousepox infection requires the complement system. | 2008 Dec |
|
| Application of two different kinds of sera against the Proteus penneri lipopolysaccharide core region in search of epitopes determining cross-reactions with antibodies. | 2008 Mar-Apr |
|
| Role of genetic polymorphisms in factor H and MBL genes in Tunisian patients with immunoglobulin A nephropathy. | 2010 |
|
| Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases. | 2010 Aug 20 |
|
| Cell membrane modification for rapid display of bi-functional peptides: a novel approach to reduce complement activation. | 2010 Jul 20 |
|
| Modulation of polymorphonuclear neutrophil functions by astrocytes. | 2010 Sep 9 |
Patents
Sample Use Guides
It was reported the action of sodium barbital as an inhibitor of rabbit-muscle creatine kinase (CK), which plays a significant role in energy homeostasis in the muscles. The activity of CK underwent a rapid decrease when the concentration of sodium barbital was increased to 8 mmol/L, and the residual activity was about 35% of then active CK. The activity of CK dropped slowly until it was almost 0 when the concentration of sodium barbital was increased to 125 mmol/L. These results indicated that sodium barbital might function as an inhibitor of CK.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
QZ6VB88G2Z
Created by
admin on Sat Dec 16 19:02:36 GMT 2023 , Edited by admin on Sat Dec 16 19:02:36 GMT 2023
|
PRIMARY | |||
|
4388-77-6
Created by
admin on Sat Dec 16 19:02:36 GMT 2023 , Edited by admin on Sat Dec 16 19:02:36 GMT 2023
|
PRIMARY | |||
|
23686184
Created by
admin on Sat Dec 16 19:02:36 GMT 2023 , Edited by admin on Sat Dec 16 19:02:36 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
